Vanguard Group Inc. Buys 50,393 Shares of STERIS plc $STE

Vanguard Group Inc. raised its position in shares of STERIS plc (NYSE:STE) by 0.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,213,521 shares of the medical equipment provider’s stock after acquiring an additional 50,393 shares during the quarter. Vanguard Group Inc. owned approximately 0.12% of STERIS worth $3,022,114,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Steigerwald Gordon & Koch Inc. purchased a new stake in STERIS in the third quarter worth $25,000. Geneos Wealth Management Inc. boosted its holdings in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 104 shares in the last quarter. Spurstone Advisory Services LLC purchased a new stake in shares of STERIS in the 2nd quarter worth about $29,000. Cloud Capital Management LLC bought a new position in shares of STERIS in the 3rd quarter worth about $29,000. Finally, TruNorth Capital Management LLC purchased a new position in STERIS during the 3rd quarter valued at about $37,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Stock Up 1.8%

NYSE:STE opened at $249.87 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. The firm has a market cap of $24.50 billion, a P/E ratio of 34.85 and a beta of 1.03. STERIS plc has a fifty-two week low of $204.90 and a fifty-two week high of $269.44. The firm has a 50-day simple moving average of $256.16 and a two-hundred day simple moving average of $250.93.

STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same quarter in the previous year, the business earned $2.32 EPS. The company’s quarterly revenue was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be paid a $0.63 dividend. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. STERIS’s payout ratio is currently 35.15%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on STE. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Wall Street Zen cut STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $275.20.

Insider Activity

In related news, VP Julia Madsen sold 5,008 shares of the stock in a transaction on Friday, November 21st. The stock was sold at an average price of $262.00, for a total transaction of $1,312,096.00. Following the sale, the vice president directly owned 10,710 shares of the company’s stock, valued at $2,806,020. This trade represents a 31.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.07% of the stock is currently owned by insiders.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.